|
JP3022967B2
(ja)
|
1985-03-15 |
2000-03-21 |
アンチバイラルズ インコーポレイテッド |
立体規則性ポリヌクレオチド結合ポリマー
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
US4828971A
(en)
|
1988-03-24 |
1989-05-09 |
Eastman Kodak Company |
Thermally processable element comprising a backing layer
|
|
CA1251835A
(en)
|
1988-04-05 |
1989-03-28 |
Wai-Cheung Tang |
Dielectric image-resonator multiplexer
|
|
WO1991004753A1
(en)
|
1989-10-02 |
1991-04-18 |
Cetus Corporation |
Conjugates of antisense oligonucleotides and therapeutic uses thereof
|
|
JP3257675B2
(ja)
|
1990-10-12 |
2002-02-18 |
マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． |
修飾リボザイム
|
|
DE4216134A1
(de)
|
1991-06-20 |
1992-12-24 |
Europ Lab Molekularbiolog |
Synthetische katalytische oligonukleotidstrukturen
|
|
US5652094A
(en)
|
1992-01-31 |
1997-07-29 |
University Of Montreal |
Nucleozymes
|
|
US5627053A
(en)
|
1994-03-29 |
1997-05-06 |
Ribozyme Pharmaceuticals, Inc. |
2'deoxy-2'-alkylnucleotide containing nucleic acid
|
|
DE69531543T2
(de)
|
1994-06-17 |
2004-06-24 |
F. Hoffmann-La Roche Ag |
N,n'-bis(chinolin-4-yl)-diamin derivate, deren herstellung und deren verwendung als antimalaria-mittel
|
|
US5716824A
(en)
|
1995-04-20 |
1998-02-10 |
Ribozyme Pharmaceuticals, Inc. |
2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
|
|
US5889136A
(en)
|
1995-06-09 |
1999-03-30 |
The Regents Of The University Of Colorado |
Orthoester protecting groups in RNA synthesis
|
|
DE69637256T2
(de)
|
1996-01-16 |
2008-06-19 |
Sirna Therapeutics, Inc., Boulder |
Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
|
|
JP4046354B2
(ja)
|
1996-03-18 |
2008-02-13 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
増大した半減期を有する免疫グロブリン様ドメイン
|
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
|
US6111086A
(en)
|
1998-02-27 |
2000-08-29 |
Scaringe; Stephen A. |
Orthoester protecting groups
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2292236T3
(es)
|
1998-04-02 |
2008-03-01 |
Genentech, Inc. |
Variantes de anticuerpos y sus fragmentos.
|
|
AU3751299A
(en)
|
1998-04-20 |
1999-11-08 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
|
GB9816575D0
(en)
|
1998-07-31 |
1998-09-30 |
Zeneca Ltd |
Novel compounds
|
|
ATE344801T1
(de)
|
1999-12-29 |
2006-11-15 |
Immunogen Inc |
Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
|
|
US8273866B2
(en)
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
|
US7833992B2
(en)
|
2001-05-18 |
2010-11-16 |
Merck Sharpe & Dohme |
Conjugates and compositions for cellular delivery
|
|
US6784291B2
(en)
|
2000-05-04 |
2004-08-31 |
Avi Biopharma, Inc. |
Splice-region antisense composition and method
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
AU2003207708A1
(en)
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US20040023220A1
(en)
|
2002-07-23 |
2004-02-05 |
Lawrence Greenfield |
Integrated method for PCR cleanup and oligonucleotide removal
|
|
AU2003260370B2
(en)
|
2002-08-05 |
2008-05-22 |
Silence Therapeutics Gmbh |
Further novel forms of interfering RNA molecules
|
|
US7956176B2
(en)
|
2002-09-05 |
2011-06-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
EP2305812A3
(en)
|
2002-11-14 |
2012-06-06 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US7498298B2
(en)
|
2003-11-06 |
2009-03-03 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
|
ATE498685T1
(de)
|
2004-06-28 |
2011-03-15 |
Univ Western Australia |
Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
|
|
WO2006132670A2
(en)
|
2004-11-12 |
2006-12-14 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the n terminus
|
|
WO2007028065A2
(en)
|
2005-08-30 |
2007-03-08 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
|
DK2735568T3
(da)
|
2006-05-10 |
2017-11-13 |
Sarepta Therapeutics Inc |
Oligonukleotidanaloger med kationiske bindinger mellem underenheder
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
AU2007282224B2
(en)
|
2006-08-11 |
2013-08-29 |
Vico Therapeutics B.V. |
Methods and means for treating DNA repeat instability associated genetic disorders
|
|
US9063129B2
(en)
|
2007-06-15 |
2015-06-23 |
Idexx Laboratories, Inc. |
Device, kit and method for hookworm antigen capture and detection
|
|
US9494131B2
(en)
|
2007-08-29 |
2016-11-15 |
Vestas Wind Systems A/S |
Monopile foundation for offshore wind turbine
|
|
AU2008317566B2
(en)
|
2007-10-26 |
2014-05-01 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
WO2009099942A2
(en)
|
2008-01-31 |
2009-08-13 |
Alnylam Pharmaceuticals, Inc. |
Chemically modified oligonucleotides and uses thereof
|
|
US20110081362A1
(en)
|
2008-01-31 |
2011-04-07 |
The Brigham And Women's Hospital, Inc. |
Treatment of cancer
|
|
EP2265283B1
(en)
|
2008-03-18 |
2014-09-03 |
Seattle Genetics, Inc. |
Auristatin drug linker conjugates
|
|
WO2009126933A2
(en)
|
2008-04-11 |
2009-10-15 |
Alnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US20110130346A1
(en)
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
CN112574988A
(zh)
|
2008-10-24 |
2021-03-30 |
萨雷普塔治疗公司 |
用于dmd的多外显子跳跃组合物
|
|
JP5786109B2
(ja)
|
2008-10-27 |
2015-09-30 |
プロセンサ テクノロジーズ ベー．フェー． |
Ｄｕｃｈｅｎｎｅ型筋ジストロフィーｍＲＮＡ前駆体のエクソン４５の効率的なスキッピングのための方法及び手段
|
|
RU2572826C2
(ru)
|
2008-12-02 |
2016-01-20 |
Чиралджен, Лтд. |
Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
|
|
CA2757354A1
(en)
|
2009-04-02 |
2010-10-07 |
Laura P.W. Ranum |
Nucleotide repeat expansion-associated polypeptides and uses thereof
|
|
CA2759899A1
(en)
|
2009-04-24 |
2010-10-28 |
Prosensa Technologies B.V. |
Oligonucleotide comprising an inosine for treating dmd
|
|
US20120172415A1
(en)
|
2009-08-31 |
2012-07-05 |
Thomas Voit |
Exon Skipping Therapy for Functional Amelioration of Semifunctional Dystrophin in Becker and Duchenne Muscular Dystrophy
|
|
WO2011044368A1
(en)
|
2009-10-07 |
2011-04-14 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
|
LT2499249T
(lt)
|
2009-11-12 |
2018-12-27 |
The University Of Western Australia |
Priešprasmės molekulės ir patologijų gydymo būdai
|
|
DK2558578T3
(en)
|
2010-04-13 |
2016-01-25 |
Life Technologies Corp |
CONFIGURATIONS AND METHODS FOR INHIBITION OF nucleic acid function
|
|
MX391454B
(es)
|
2010-04-15 |
2025-03-05 |
Seagen Inc |
Compuesto de engarce-fármaco para conjugación a una unidad de ligando.
|
|
US8697688B2
(en)
|
2010-04-15 |
2014-04-15 |
Seattle Genetics Inc. |
Pyrrolobenzodiazepines used to treat proliferative diseases
|
|
KR20200133284A
(ko)
|
2010-05-28 |
2020-11-26 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
|
|
IT1400425B1
(it)
|
2010-06-08 |
2013-05-31 |
Amsterdam Molecular Therapeutics Bv |
Modified snrnas for use in therapy.
|
|
EP2580326A1
(en)
|
2010-06-11 |
2013-04-17 |
Antisense Pharma GmbH |
Method for selective oligonucleotide modification
|
|
WO2012012467A2
(en)
|
2010-07-19 |
2012-01-26 |
Isis Pharmaceuticals, Inc. |
Modulation of nuclear-retained rna
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
US8501930B2
(en)
|
2010-12-17 |
2013-08-06 |
Arrowhead Madison Inc. |
Peptide-based in vivo siRNA delivery system
|
|
EP2672977A1
(en)
|
2011-02-08 |
2013-12-18 |
The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System |
Antisense oligonucleotides
|
|
SG10201602394QA
(en)
|
2011-03-29 |
2016-05-30 |
Roche Glycart Ag |
Antibody FC Variants
|
|
EP2732035A2
(en)
|
2011-07-15 |
2014-05-21 |
Sarepta Therapeutics, Inc. |
Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
|
|
AU2012284265B2
(en)
|
2011-07-19 |
2017-08-17 |
Wave Life Sciences Ltd. |
Methods for the synthesis of functionalized nucleic acids
|
|
ES2945932T3
(es)
|
2011-10-14 |
2023-07-10 |
Seagen Inc |
Pirrolobenzodiazepinas y conjugados dirigidos
|
|
EP2780454A2
(en)
|
2011-11-18 |
2014-09-24 |
Alnylam Pharmaceuticals, Inc. |
Modified rnai agents
|
|
CN117721110A
(zh)
|
2011-12-28 |
2024-03-19 |
日本新药株式会社 |
反义核酸
|
|
CN112251436A
(zh)
|
2012-01-27 |
2021-01-22 |
比奥马林技术公司 |
治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
|
|
WO2013121175A1
(en)
|
2012-02-16 |
2013-08-22 |
Ucl Business Plc |
Lysosome-cleavable linker
|
|
US9981046B2
(en)
|
2012-05-15 |
2018-05-29 |
Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. |
Drug-conjugates, conjugation methods, and uses thereof
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
JP6453212B2
(ja)
|
2012-07-13 |
2019-01-16 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
キラル制御
|
|
CN104837502B
(zh)
|
2012-10-12 |
2018-08-10 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
|
US10131682B2
(en)
|
2012-11-24 |
2018-11-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
|
|
RU2015129800A
(ru)
|
2012-12-21 |
2017-01-30 |
Биоэллаенс К. В. |
Гидрофильные саморазрушающиеся линкеры и их конъюгаты
|
|
NZ731587A
(en)
|
2013-03-14 |
2021-07-30 |
Sarepta Therapeutics Inc |
Exon skipping compositions for treating muscular dystrophy
|
|
CA2906812A1
(en)
|
2013-03-15 |
2014-09-18 |
Sarepta Therapeutics, Inc. |
Improved compositions for treating muscular dystrophy
|
|
MX379256B
(es)
|
2013-03-15 |
2025-03-10 |
Regeneron Pharma |
Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos.
|
|
EP2777714A1
(en)
|
2013-03-15 |
2014-09-17 |
NBE-Therapeutics LLC |
Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
|
|
US9295731B2
(en)
|
2013-04-01 |
2016-03-29 |
Mark Quang Nguyen |
Cleavable drug conjugates, compositions thereof and methods of use
|
|
WO2014177042A1
(zh)
|
2013-04-28 |
2014-11-06 |
Qin Gang |
一种新型的连接子及其制备方法和用途
|
|
WO2014190441A1
(en)
|
2013-05-31 |
2014-12-04 |
Zymeworks Inc. |
Heteromultimers with reduced or silenced effector function
|
|
US11229711B2
(en)
|
2013-06-06 |
2022-01-25 |
Magenta Therapeutics, Inc. |
Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
WO2015038426A1
(en)
|
2013-09-13 |
2015-03-19 |
Asana Biosciences, Llc |
Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
|
|
ES2826398T3
(es)
|
2013-10-15 |
2021-05-18 |
Seagen Inc |
Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco
|
|
WO2015057876A1
(en)
|
2013-10-15 |
2015-04-23 |
Sorrento Therapeutics Inc. |
Drug-conjugates with a targeting molecule and two different drugs
|
|
SMT201900169T1
(it)
|
2014-03-12 |
2019-05-10 |
Nippon Shinyaku Co Ltd |
Acido nucleico antisenso
|
|
RU2695430C2
(ru)
|
2014-06-17 |
2019-07-23 |
Ниппон Синяку Ко., Лтд. |
Антисмысловые нуклеиновые кислоты
|
|
CN104498614B
(zh)
*
|
2014-12-31 |
2017-07-11 |
广州和泰科技有限公司 |
假肥大型肌营养不良症的检测探针及其无创检测试剂盒
|
|
EP3286318A2
(en)
|
2015-04-22 |
2018-02-28 |
Mina Therapeutics Limited |
Sarna compositions and methods of use
|
|
EP3297649B1
(en)
|
2015-05-19 |
2023-10-11 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
MX391086B
(es)
|
2015-06-24 |
2025-03-21 |
Hoffmann La Roche |
Anticuerpos anti-receptor de transferrina con afinidad diseñada.
|
|
SI3351633T1
(sl)
|
2015-09-15 |
2020-09-30 |
Nippon Shinyaku Co., Ltd. |
Protismiselna nukleinska kislina
|
|
EP3858993A1
(en)
|
2015-10-09 |
2021-08-04 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
WO2017148880A1
(en)
|
2016-03-01 |
2017-09-08 |
F. Hoffmann-La Roche Ag |
Obinutuzumab variants having altered cell death induction
|
|
JP2019513371A
(ja)
|
2016-04-01 |
2019-05-30 |
アビディティー バイオサイエンシーズ エルエルシー |
核酸ポリペプチド組成物とその使用
|
|
WO2017192679A1
(en)
|
2016-05-04 |
2017-11-09 |
Wave Life Sciences Ltd. |
Methods and compositions of biologically active agents
|
|
CN109310765A
(zh)
|
2016-06-20 |
2019-02-05 |
领先基因生物技术股份有限公司 |
抗体-药物偶联物
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
CA3029772A1
(en)
*
|
2016-07-05 |
2018-01-11 |
Biomarin Technologies B.V. |
Pre-mrna splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
|
|
US20190330626A1
(en)
|
2016-07-15 |
2019-10-31 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for use in dystrophin transcript
|
|
MX2019008199A
(es)
|
2017-01-06 |
2019-11-25 |
Avidity Biosciences Llc |
Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
US20200282074A1
(en)
*
|
2017-09-22 |
2020-09-10 |
Avidity Biosciences, Inc. |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
|
JP7506601B2
(ja)
|
2017-12-06 |
2024-06-26 |
アビディティー バイオサイエンシーズ，インク． |
筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
|
|
US10910559B2
(en)
|
2018-06-01 |
2021-02-02 |
Massachusetts Institute Of Technology |
Optoelectronic memristor devices including one or more solid electrolytes with electrically controllable optical properties
|
|
EP3829595A4
(en)
*
|
2018-08-02 |
2022-08-24 |
Dyne Therapeutics, Inc. |
MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
|
|
WO2020102287A1
(en)
|
2018-11-14 |
2020-05-22 |
University Of Hawaii |
Compositions and methods for the synthesis and identification of covalent aptamers
|
|
IL312067B2
(en)
|
2018-12-21 |
2025-08-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and uses thereof
|
|
WO2021113390A1
(en)
*
|
2019-12-02 |
2021-06-10 |
Shape Therapeutics Inc. |
Compositions for treatment of diseases
|
|
WO2021142313A1
(en)
*
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof
|
|
EP4366783A4
(en)
|
2021-07-09 |
2025-08-27 |
Dyne Therapeutics Inc |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF DYSTROPHINOPATHIES
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|